Two drugs look promising for lipoprotein(a), a common genetic risk factor for heart disease At AHA, Phase 2 results are seen as sign that ‘major new path’ of therapy is opening

https://www.statnews.com/2024/11/18/lipoprotein-a-heart-risk-aha-eli-lilly-silence-therapeutics/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz--2O4ZVNSTJx1TmeLNd5FdGLMUxvEnn1VlPR-OkK2tAMLq9Ysa6Tsvz3RM-aS5x-gl6nRnHj8iU8SF1gA9waBi5lxfTWw&_hsmi=334535734&utm_content=334535734&utm_source=hs_email Between President-elect Trump’s return to power, the proliferation of GLP-1 medications, and promising trial data for two medications targeting a common risk factor for cardiovascular disease, there was no shortage of conversation topics at the American Heart Association’s conference in Chicago. One attention-getting presentation offered scientific details from the SUMMIT trial, which looked at tirzepatide versus placebo in 731 people who have heart failure with preserved ejection fraction, or HFpEF. The drug,sold as Mounjaro (diabetes) and Zepbound (obesity), lowered the risk of heart failure becoming worse or cardiovascular death occurring in adults with obesity. Separately, Eli Lilly and Silence Therapeutics both reported promising data on drug candidates meant to lower lipoprotein(a) levels, a promising development for a serious cardiovascular disease risk factor that isn’t impacted by statins, diet, or exercise. AHA 2024: First, a call for prevention. Then a spotlight on obesity drugs As cardiovascular disease rises, studies assess tools old and new https://www.statnews.com/2024/11/18/aha-news-prevention-obesity-drugs-hypertension/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz--rtWsRIS8iIkDErlQSKpwg3HpsMFTPnRpMgSHSVIulpuRnUCtGLPdgs9Yv1VD53GlaA6y4YwRqTJw_uKgAbv0cug2xtw&_hsmi=334535734&utm_content=334535734&utm_source=hs_email